Pfizer Inc
PFE24.370USD
+0.580+2.44%
Close 04/30, 16:00（ET）Quotes delayed by 15 min
138.10BMarket Cap
17.20P/E TTM
More Details of Pfizer Inc Company
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
Company Info
Company codePFE
Company namePfizer Inc
IPO dateJan 17, 1944
Founded at1942
CEODr. Albert Bourla, Ph.D.
Number of employees81000
Security typeOrdinary Share
Fiscal year-endJan 17
Address66 Hudson Boulevard East
CityNEW YORK
Stock exchangeNYSE Consolidated
CountryUnited States of America
Postal code10001-2192
Phone12127332323
Websitehttps://www.pfizer.com/
Company codePFE
IPO dateJan 17, 1944
Founded at1942
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Albert Bourla, Ph.D.
Dr. Albert Bourla, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
372.89K
+10.54%
Mr. Douglas M. Lankler
Mr. Douglas M. Lankler
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
161.04K
+8.26%
Ms. Sally Susman
Ms. Sally Susman
Executive Vice President, Chief Corporate Affairs Officer
Executive Vice President, Chief Corporate Affairs Officer
95.94K
+8.23%
Mr. Michael (Ike) Mcdermott
Mr. Michael (Ike) Mcdermott
Executive Vice President, Chief Global Supply Officer
Executive Vice President, Chief Global Supply Officer
70.77K
-0.78%
Mr. Ronald E. Blaylock
Mr. Ronald E. Blaylock
Independent Director
Independent Director
32.46K
+149.67%
Ms. Lidia L. Fonseca, Ph.D.
Ms. Lidia L. Fonseca, Ph.D.
Executive Vice President, Chief Digital and Technology Officer
Executive Vice President, Chief Digital and Technology Officer
30.96K
--
Mr. Aamir Malik
Mr. Aamir Malik
Executive Vice President, Chief US Commercial Officer
Executive Vice President, Chief US Commercial Officer
29.55K
+7.80K%
Ms. Payal Sahni
Ms. Payal Sahni
Executive Vice President, Chief People Experience Officer
Executive Vice President, Chief People Experience Officer
24.85K
+6.62%
Mr. Cyrus Taraporevala
Mr. Cyrus Taraporevala
Independent Director
Independent Director
10.00K
--
Dr. Scott Gottlieb, M.D.
Dr. Scott Gottlieb, M.D.
Independent Director
Independent Director
10.00K
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Albert Bourla, Ph.D.
Dr. Albert Bourla, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
372.89K
+10.54%
Mr. Douglas M. Lankler
Mr. Douglas M. Lankler
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
161.04K
+8.26%
Ms. Sally Susman
Ms. Sally Susman
Executive Vice President, Chief Corporate Affairs Officer
Executive Vice President, Chief Corporate Affairs Officer
95.94K
+8.23%
Mr. Michael (Ike) Mcdermott
Mr. Michael (Ike) Mcdermott
Executive Vice President, Chief Global Supply Officer
Executive Vice President, Chief Global Supply Officer
70.77K
-0.78%
Mr. Ronald E. Blaylock
Mr. Ronald E. Blaylock
Independent Director
Independent Director
32.46K
+149.67%
Ms. Lidia L. Fonseca, Ph.D.
Ms. Lidia L. Fonseca, Ph.D.
Executive Vice President, Chief Digital and Technology Officer
Executive Vice President, Chief Digital and Technology Officer
30.96K
--
Revenue Breakdown
Currency: USDUpdate time: Sun, Apr 6
Currency: USDUpdate time: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Eliquis alliance revenues and direct sales
7.37B
11.58%
Prevnar family
6.41B
10.08%
Paxlovid
5.72B
8.98%
Vyndaqel family
5.45B
8.57%
Comirnaty
5.35B
8.41%
Other
33.33B
52.38%
By RegionUSD
Name
Revenue
Proportion
United States
38.69B
60.81%
Developed Markets
16.06B
25.24%
Emerging Markets
8.88B
13.95%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Eliquis alliance revenues and direct sales
7.37B
11.58%
Prevnar family
6.41B
10.08%
Paxlovid
5.72B
8.98%
Vyndaqel family
5.45B
8.57%
Comirnaty
5.35B
8.41%
Other
33.33B
52.38%
Shareholder
Update time: Fri, Feb 21
Update time: Fri, Feb 21
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
The Vanguard Group, Inc.
9.10%
State Street Global Advisors (US)
5.12%
BlackRock Institutional Trust Company, N.A.
4.93%
Charles Schwab Investment Management, Inc.
2.74%
Wellington Management Company, LLP
2.47%
Other
75.64%
Shareholder Statistics
Shareholder
Proportion
The Vanguard Group, Inc.
9.10%
State Street Global Advisors (US)
5.12%
BlackRock Institutional Trust Company, N.A.
4.93%
Charles Schwab Investment Management, Inc.
2.74%
Wellington Management Company, LLP
2.47%
Other
75.64%
Type
Shareholder
Proportion
Investment Advisor/Hedge Fund
31.03%
Investment Advisor
25.23%
Research Firm
2.95%
Pension Fund
2.23%
Bank and Trust
1.85%
Hedge Fund
1.73%
Sovereign Wealth Fund
1.64%
Insurance Company
1.18%
Holding Company
0.04%
Other
32.12%
Institutional Shareholding
Update time: Fri, Feb 21
Update time: Fri, Feb 21
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
4989
3.87B
68.15%
-55.82M
2024Q4
5153
3.84B
67.74%
-83.26M
2024Q3
5005
3.85B
67.99%
-51.77M
2024Q2
5026
3.84B
67.75%
-120.77M
2024Q1
5032
3.89B
68.71%
-120.39M
2023Q4
5089
3.97B
70.25%
-96.67M
2023Q3
4952
4.00B
70.89%
-71.80M
2023Q2
4962
4.02B
71.16%
-62.35M
2023Q1
4947
4.02B
71.28%
-30.98M
2022Q4
4927
4.01B
71.39%
-30.90M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
515.98M
9.1%
+2.34M
+0.46%
Dec 31, 2024
State Street Global Advisors (US)
290.48M
5.12%
+23.75K
+0.01%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
279.54M
4.93%
+4.29M
+1.56%
Dec 31, 2024
Charles Schwab Investment Management, Inc.
155.46M
2.74%
+25.32M
+19.45%
Dec 31, 2024
Wellington Management Company, LLP
139.99M
2.47%
-23.74M
-14.50%
Dec 31, 2024
Geode Capital Management, L.L.C.
120.59M
2.13%
+2.92M
+2.48%
Dec 31, 2024
Norges Bank Investment Management (NBIM)
87.79M
1.55%
+3.82M
+4.55%
Dec 31, 2024
MFS Investment Management
74.22M
1.31%
+5.45M
+7.92%
Dec 31, 2024
State Farm Insurance Companies
54.51M
0.96%
--
--
Dec 31, 2024
BlackRock Asset Management Ireland Limited
45.96M
0.81%
+2.00M
+4.55%
Dec 31, 2024
View more
Related ETFs
Update time: Sun, Apr 6
Update time: Sun, Apr 6
Name
Proportion
First Trust NASDAQ Pharmaceuticals ETF
7.69%
First Trust Morningstar Dividend Leaders Index Fund
7.46%
Parnassus Value Select ETF
6.15%
Amplify Weight Loss Drug & Treatment ETF
5.44%
Invesco Pharmaceuticals ETF
5%
NYLI Healthy Hearts ETF
4.77%
Vaneck Durable High Dividend ETF
4.65%
VanEck Pharmaceutical ETF
4.65%
ProShares Smart Materials ETF
4.3%
VanEck Morningstar Wide Moat Value ETF
4.28%
View more
First Trust NASDAQ Pharmaceuticals ETF
Proportion7.69%
First Trust Morningstar Dividend Leaders Index Fund
Proportion7.46%
Parnassus Value Select ETF
Proportion6.15%
Amplify Weight Loss Drug & Treatment ETF
Proportion5.44%
Invesco Pharmaceuticals ETF
Proportion5%
NYLI Healthy Hearts ETF
Proportion4.77%
Vaneck Durable High Dividend ETF
Proportion4.65%
VanEck Pharmaceutical ETF
Proportion4.65%
ProShares Smart Materials ETF
Proportion4.3%
VanEck Morningstar Wide Moat Value ETF
Proportion4.28%
Dividend
A total of
44.91B
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Dec 12, 2024
PFE.NB Interim Cash Dividend of gross USD 0.43 paid on Mar 07, 2025 going ex on Jan 24, 2025
Jan 24, 2025
Mar 07, 2025
Jan 24, 2025
Oct 09, 2024
PFE.NB Final Cash Dividend of gross USD 0.42 paid on Dec 02, 2024 going ex on Nov 08, 2024
Nov 08, 2024
Dec 02, 2024
Nov 08, 2024
Jun 26, 2024
PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Sep 03, 2024 going ex on Jul 26, 2024
Jul 26, 2024
Sep 03, 2024
Jul 26, 2024
Apr 24, 2024
PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Jun 14, 2024 going ex on May 09, 2024
May 10, 2024
Jun 14, 2024
May 09, 2024
Dec 14, 2023
PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Mar 01, 2024 going ex on Jan 25, 2024
Jan 26, 2024
Mar 01, 2024
Jan 25, 2024
Oct 04, 2023
PFE.NB Final Cash Dividend of gross USD 0.41 paid on Dec 04, 2023 going ex on Nov 09, 2023
Nov 10, 2023
Dec 04, 2023
Nov 09, 2023
Jun 22, 2023
PFE.NB Interim Cash Dividend of gross USD 0.41 paid on Sep 05, 2023 going ex on Jul 27, 2023
Jul 28, 2023
Sep 05, 2023
Jul 27, 2023
Apr 26, 2023
PFE.NB Interim Cash Dividend of gross USD 0.41 paid on Jun 09, 2023 going ex on May 11, 2023
May 12, 2023
Jun 09, 2023
May 11, 2023
Dec 09, 2022
PFE.NB Interim Cash Dividend of gross USD 0.41 paid on Mar 03, 2023 going ex on Jan 26, 2023
Jan 27, 2023
Mar 03, 2023
Jan 26, 2023
Sep 22, 2022
PFE.NB Final Cash Dividend of gross USD 0.4 paid on Dec 05, 2022 going ex on Nov 03, 2022
Nov 04, 2022
Dec 05, 2022
Nov 03, 2022
View more
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data